Crescent Biopharma Ownership | Who Owns Crescent Biopharma?
Crescent Biopharma Ownership Summary
Crescent Biopharma is owned by 95.54% institutional investors, 0.42% insiders, and 4.04% retail investors. Fmr is the largest institutional shareholder, holding 3.97% of CBIO shares. Fidelity Small Cap Growth is the top mutual fund, with 2.56% of its assets in Crescent Biopharma shares.
CBIO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Crescent Biopharma | 95.54% | 0.42% | 4.04% |
| Sector | Healthcare Stocks | 245.53% | 12.09% | -157.62% |
| Industry | Biotech Stocks | 381.70% | 11.71% | -293.40% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fmr | 4.13M | 3.97% | $75.93M |
| Bvf inc/il | 2.75M | 2.64% | $50.49M |
| Fairmount funds management | 2.75M | 2.64% | $50.48M |
| Vr adviser | 2.13M | 2.05% | $39.19M |
| Fcpm iii services b.v. | 1.68M | 1.61% | $30.82M |
| Balyasny asset management | 1.51M | 1.45% | $27.74M |
| Vestal point capital, lp | 1.50M | 1.44% | $27.55M |
| Opaleye management | 1.31M | 1.26% | $24.11M |
| Tang capital management | 1.16M | 1.11% | $21.31M |
| Logos global management lp | 482.50K | 0.46% | $8.86M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Fcpm iii services b.v. | 1.68M | 4.27% | $30.82M |
| Fairmount funds management | 2.75M | 3.65% | $50.48M |
| Opaleye management | 1.31M | 3.18% | $24.11M |
| Bvf inc/il | 2.75M | 1.61% | $50.49M |
| Vr adviser | 2.13M | 1.46% | $39.19M |
| Exome asset management | 153.19K | 1.46% | $2.81M |
| Tang capital management | 1.16M | 1.08% | $21.31M |
| Vestal point capital, lp | 1.50M | 0.77% | $27.55M |
| Stonepine capital management | 85.00K | 0.63% | $1.56M |
| Logos global management lp | 482.50K | 0.44% | $8.86M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Balyasny asset management | 1.51M | 0.04% | 1.40M |
| Tang capital management | 1.16M | 1.08% | 287.60K |
| Millennium management | 323.55K | 0.00% | 261.67K |
| Marshall wace, llp | 200.78K | 0.00% | 178.95K |
| Exome asset management | 153.19K | 1.46% | 153.19K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | - | - | -642.72K |
| Boxer capital management | - | - | -453.69K |
| Deep track capital, lp | - | - | -453.69K |
| Driehaus capital management | - | - | -302.46K |
| Frazier life sciences management | - | - | -272.95K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Exome asset management | 153.19K | 1.46% | 153.19K | $2.81M |
| Jennison associates | 152.97K | 0.00% | 152.97K | $2.81M |
| Silverarc capital management | 130.50K | 0.24% | 130.50K | $2.40M |
| Vanguard fiduciary trust | 49.42K | 0.00% | 49.42K | $907.90K |
| Barclays | 30.19K | 0.00% | 30.19K | $554.57K |
Sold Out
| Holder | Change |
|---|---|
| Group one trading | -4.00 |
| Raymond james financial | -50.00 |
| Tower research capital llc (trc) | -409.00 |
| Cannon global investment management | -10.20K |
| Verdad advisers, lp | -12.75K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 82 | 36.67% | 29,169,175 | 16.15% | 95 | 1.40% | 51 | 50.00% | 14 | 75.00% |
| Mar 31, 2026 | 58 | 7.41% | 25,034,144 | 5.44% | 24 | 3.52% | 33 | -10.81% | 7 | -22.22% |
| Dec 31, 2025 | 11 | -72.50% | 904,390 | -92.01% | - | 634.79% | 5 | -77.27% | 5 | -37.50% |
| Sep 30, 2025 | 7 | -75.86% | 837,114 | -92.21% | - | 27.94% | 5 | -82.76% | 1 | - |
| Jun 30, 2025 | 29 | - | 10,751,740 | - | 1,244 | - | 29 | - | - | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Fidelity Small Cap Growth | 950.82K | 2.56% | 432.29K |
| Vanguard MStar Total Stk Mkt Idx Invest | 906.65K | 2.44% | - |
| Vanguard Total Stock Mkt Idx Inv | 661.95K | 2.40% | - |
| iShares Russell 2000 ETF | 738.08K | 1.99% | -8.51K |
| Vanguard Morn Total Stk Mkt Idx Investor | 661.95K | 1.79% | - |
| Fidelity Small Cap Growth K6 | 461.30K | 1.24% | 221.49K |
| Fidelity Growth Compy Commingled Pl S | 433.42K | 1.17% | - |
| Fidelity Advisor Biotechnology I | 356.09K | 0.96% | 6.70K |
| State Street® SPDR® S&P® Biotech ETF | 334.66K | 0.90% | -6.40K |
| PGIM Jennison Health Sciences Z | 311.39K | 0.84% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 16, 2026 | Lynch Ryan | See Remarks | Sell | $4.30K |
| Sep 16, 2026 | Pinkas Jan | Chief Scientific Officer | Sell | $11.78K |
| Sep 16, 2026 | Im Ellie Eunkyung | Chief Medical Officer | Sell | $11.15K |
| Sep 16, 2026 | Scalzo Richard William | Chief Financial Officer | Sell | $10.17K |
| Sep 16, 2026 | Bispham Barbara Harlin | See Remarks | Sell | $11.10K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | 2 | 9 |
| 2026 Q2 | - | 7 |
| 2025 Q4 | 2 | - |
| 2025 Q3 | - | - |
| 2025 Q2 | - | - |
CBIO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools